# Shanghai BiOligo Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-bioligo-biotech-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.bioligo.cn
- Total disclosed funding: $47M
- Latest round: Series A (Oct 22, 2021)
- Investors on record: 3

## About

Established in 2011 and based in Shanghai, China, Shanghai BiOligo Biotech Co., Ltd is a medical company that focuses on research, development and sales of in vitro diagnostic products and nucleic acid drugs. The company's mainly involved in the field of virus testing, screening of serious diseases, genetic drug development and research, forensic identification, quarantine and food safety monitoring. The core team has more than 10 years of experience in the field of test probe and primer.

The company's provides industrial-grade probe or primer synthesis, DNA sequencing services, total gene synthesis services and SNP (single nucleotide polymorphism) genotyping services for customers.

## Funding rounds

- Series A, Oct 22, 2021, $47M — Carlyle Group, China International Capital Corporation, YuanBio Venture

## Investors

- Carlyle Group (https://capitalatlas.ai/funds/carlyle-group) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A